CELL-DERIVED VESICLES ENGINEERED WITH ANCHOR PROTEINS AND USE THEREOF
The present invention relates to engineered cell-derived vesicles (CDVs) that can be used as a drug delivery system, and was completed by discovering four types of anchor proteins that match the intrinsic characteristics of CDVs and can mediate the stable introduction of biologically active molecules. The anchor proteins are CDV-specific membrane proteins that are abundantly present, and it was confirmed that CDVs comprising the anchor proteins can be more stably loaded with biologically active molecules. For example, as a result of carrying out comparative experiments by using a fluorescent protein, it was confirmed that CDVs into which the anchor proteins are introduced were more effectively loaded with the fluorescent protein, compared to CDVs without the anchor proteins. It was also confirmed that, when a cancer cell-targeting antibody was loaded into the engineered CDVs of the present invention, the engineered CDVs exhibited an increased ability to target cancer cells and were more effectively absorbed into cancer cells. That is, the CDVs of the present invention are BioDrone engineered with the anchor proteins and can be stably loaded with various biologically active molecules and deliver same to a target of interest, and thus are expected to be used as a platform for the delivery of various drugs and treatment..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 18. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KWON YERIM [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-18, Last update posted on www.tib.eu: 2024-02-23, Last updated: 2024-03-01 |
|---|
| Patentnummer: |
WO2024014907 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019102860 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019102860 | ||
| 003 | DE-627 | ||
| 005 | 20240301100721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019102860 | ||
| 035 | |a (EPA)WO2024014907 | ||
| 035 | |a (EPA)89537108 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a KWON YERIM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CELL-DERIVED VESICLES ENGINEERED WITH ANCHOR PROTEINS AND USE THEREOF |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-18, Last update posted on www.tib.eu: 2024-02-23, Last updated: 2024-03-01 | ||
| 520 | |a The present invention relates to engineered cell-derived vesicles (CDVs) that can be used as a drug delivery system, and was completed by discovering four types of anchor proteins that match the intrinsic characteristics of CDVs and can mediate the stable introduction of biologically active molecules. The anchor proteins are CDV-specific membrane proteins that are abundantly present, and it was confirmed that CDVs comprising the anchor proteins can be more stably loaded with biologically active molecules. For example, as a result of carrying out comparative experiments by using a fluorescent protein, it was confirmed that CDVs into which the anchor proteins are introduced were more effectively loaded with the fluorescent protein, compared to CDVs without the anchor proteins. It was also confirmed that, when a cancer cell-targeting antibody was loaded into the engineered CDVs of the present invention, the engineered CDVs exhibited an increased ability to target cancer cells and were more effectively absorbed into cancer cells. That is, the CDVs of the present invention are BioDrone engineered with the anchor proteins and can be stably loaded with various biologically active molecules and deliver same to a target of interest, and thus are expected to be used as a platform for the delivery of various drugs and treatment. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a PARK SUNG-SOO |4 aut | |
| 700 | 0 | |a OH SEUNG WOOK |4 aut | |
| 700 | 0 | |a BAE SHIN GYU |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 18. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:18 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89537108/publication/WO2024014907A1?q=WO2024014907 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 18 |c 01 | ||